“we identify that the causal gene, ETS2, is a central regulator of human inflammatory macrophages”
Their drugable pathway involves MEK inhibition which is downregulated by Leronlimab per OHM…interesting to note that direct approach’s to inhibition seem to be associated with significant side effects.
https://www.nature.com/articles/s41586-024-07501-1